Advaxis commences enrollment in ADXS-HPV Phase 1/2 study for neck and head cancer Advaxis.

Related StoriesCornell biomedical engineers develop 'super natural killer cells' to destroy cancers cells in lymph nodesNew antenna-like device makes breasts cancer surgery much easier for surgeonsStudy shows uncommon HER2 missense mutations usually do not spread breast cancer on their ownThomas A. Moore, Chairman & CEO of Advaxis commented, ‘We are very happy to be dealing with an internationally-famous oncology group to further expand the ADXS-HPV scientific development program to some other HPV-associated tumor type.A therapeutic agent due to the program could represent a novel method of dealing with types of cancers with obtained level of resistance to Raf and Mek inhibitors. Our business advancement team is already engaged in discussions with celebrations who’ve previously expressed an interest inside our use Erk inhibitors.’.

The bark scorpion can measure only 3 inches long and still pack a deadly sting. But this very small creature has fulfilled its match in an exceedingly small medical trial. The merchandise, called Anascorp, is an antivenom created from the plasma of horses injected with venom from the scorpion.